Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.68 |
| ▸ | ECE1 | P42892 | 12/20 | 0.63 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641793 | 0.96 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL21641791 | 0.96 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL29380886 | 0.96 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL21641792 | 0.96 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL30051858 | 0.93 | ACE (0.69) | ACEECE1ALOX15 | |
| SCHEMBL30465920 | 0.92 | ACE (0.64) | ACEECE1 | |
| SCHEMBL29750422 | 0.91 | ACE (0.67) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL3497589 | 0.90 | ACE (0.72) | ACEECE1ALOX15 | |
| SCHEMBL30051627 | 0.90 | ACE (0.72) | ACEECE1ALOX15 | |
| SCHEMBL30123268 | 0.90 | ACE (0.66) | ACEECE1ERAP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12449422-B2 | Method and composition matter for immunoproteasome-mediated delivery into living cells | PURDUE RESEARCH FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20220120756-A1 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | PURDUE RESEARCH FOUNDATION (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220120756-A1 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | EXOSC5, PSMG3, EXOSC4 | ACE 563/4885ECE1 1178/4885ERAP2 105/4885 |
| US-12449422-B2 | Method and composition matter for immunoproteasome-mediated delivery into living cells | EXOSC5, PSMG3, EXOSC4 | ACE 563/4885ECE1 1178/4885ERAP2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.